Have you lost your mind?
You sound like Hans Christian Andersen reborn with such fairy tales
They are...it's called getting vaccinated, not pretending to be a doctor, pharmacist or medical researcher when they have no experience and certainly no qualification (other than Google & play-pretend).
amp.theguardian.com
...yet when a specialist doctor at Groote Schuur said a couple of weeks that there were no vaccinated people in serious condition at that hospital, but that he couldn't say the same about people using IVM he got slandered and torn apart by 2 or 3 zealots here.
Can you see both the irony and hypocrisy of every single argument before and after when it comes to the vaccine...!
Its fine, because they'll simply Google their law qualification/experience/knowledge and then be able to argue successfully against qualified lawyers and advocates.
academic.oup.com
bmcinfectdis.biomedcentral.com
c19ivermectin.com
jamanetwork.com
www.dovepress.com
www.longdom.org
www.mdpi.com
www.medrxiv.org
www.medrxiv.org
www.researchsquare.com
www.sciencedirect.com
www.sciencedirect.com
www.sciencedirect.com
www.sciencedirect.com
Do you have a thick skin? A hard hat, decent earmuffs and eye guards? Incoming attacks from all sides are on the way. Quite a list of links you have posted, most of which I have read already but will still work through all of them.
Ignore the mindless low-IQ NPCBots dismissing it as "horse-paste", the reality is many doctors are using Ivermectin on the frontlines in the arsenal against covid, and here's a partial list of actual scientific studies that have so far found improved outcomes with early treatment Ivermectin:
Ivermectin shows clinical benefits in mild to moderate COVID19: a randomized controlled double-blind, dose-response study in Lagos
Summary Introduction. In vitro studies have shown the efficacy of Ivermectin (IV) to inhibit the SARS—CoV-2 viral replication, but questions remained as to in-v
Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial - BMC Infectious Diseases
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has changed our lives. The scientific community has been investigating re-purposed treatments to prevent disease progression in coronavirus disease (COVID-19) patients. Objective To determine whether ivermectin treatment can...
Shouman: Use of Ivermectin as a Potential Chemoprophylaxis for COVID-19 in Egypt: A Randomised Clinical Trial
Shouman, 304 patient ivermectin prophylaxis RCT: 91% fewer symptomatic cases [p=0.001] and 93% lower severe cases [p=0.002]. PEP trial for asymptomatic close..
Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19
This randomized trial compares the effects of ivermectin vs placebo on time to symptom resolution within 21 days among patients with mild COVID-19.
SAGE Journals: Your gateway to world-class research journals
Subscription and open access journals from SAGE Publishing, the world's leading independent academic publisher.journals.sagepub.com
Error - Cookies Turned Off
onlinelibrary.wiley.com
Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting
BACKGROUND: SARS-CoV-2 infection (COVID-19) is a potentially lethal disease that may progress into severe respiratory distress syndrome requiring ventilatorypapers.ssrn.com
Using ivermectin in treating of patients with mild COVID-19 | IJN
Clinical, biochemical and molecular evaluations of ivermectin mucoadhesive nanosuspension nasal spray in reducing upper respiratory symptoms of mild COVID-19
Longdom Publishing SL | Open Access Journals
Longdom Publishing SL is one of the leading international open access journals publishers, covering clinical, medical, and technology-oriented subjects
Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon
Objective: This study was designed to determine the efficacy of ivermectin, an FDA-approved drug, in producing clinical benefits and decreasing the viral load of SARS-CoV-2 among asymptomatic subjects that tested positive for this virus in Lebanon. Methods: A randomized controlled trial was...
Efficacy of Ivermectin in COVID-19 Patients with Mild to Moderate Disease
Objective To evaluate the efficacy of ivermectin (IVM) as an addition to the standard of care (SOC) treatment in COVID-19 patients with mild and moderate disease Materials and Methods A randomized clinical trial (Trial registration # [NCT04392713][1]) was carried out at Combined Military...
Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19 – A double-blind, randomized placebo-controlled trial
Background Ivermectin, an anti-parasitic agent, also has anti-viral properties. Our aim was to assess whether ivermectin can shorten the viral shedding in patients at an early-stage of COVID-19 infection. Methods The double-blinded trial compared patients receiving ivermectin 0·2 mg/kg for 3...
Cluster Randomised Trials - Ivermectin Repurposing For COVID-19 Treatment Of Outpatients With Mild Disease In Primary Health Care Centers
Background The emergency of COVID-19, along with the current difficulties in responding to the high demand for vaccines, requests to the scientific community to find alternative treatments based on reuse of drugs as a strategy to prevent the progression of the disease in patie...
A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness
Ivermectin, a US Food and Drug Administration-approved anti-parasitic agent, was found to inhibit severe acute respiratory syndrome coronavirus 2 (SAR…
Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial
Ivermectin is an antiparasitic drug which has in-vitro efficacy in reducing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) viral load. H…
Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients
In a prospective observational study (pre-AndroCoV Trial), the use of nitazoxanide, ivermectin and hydroxychloroquine demonstrated unexpected improvem…
Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial
There are limited antiviral options for the treatment of patients with COVID-19. Ivermectin (IVM), a macrocyclic lactone with a wide anti-parasitary s…
Are all these studies wrong? Maybe, but nobody has demonstrated that scientifically at all. Not even close. Is more research needed? Yes.
Cool, have you examined the Cochrane meta yet?Ignore the mindless low-IQ NPCBots dismissing it as "horse-paste", the reality is many doctors are using Ivermectin on the frontlines in the arsenal against covid, and here's a partial list of actual scientific studies that have so far found improved outcomes with early treatment Ivermectin:
Ivermectin shows clinical benefits in mild to moderate COVID19: a randomized controlled double-blind, dose-response study in Lagos
Summary Introduction. In vitro studies have shown the efficacy of Ivermectin (IV) to inhibit the SARS—CoV-2 viral replication, but questions remained as to in-v
Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial - BMC Infectious Diseases
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has changed our lives. The scientific community has been investigating re-purposed treatments to prevent disease progression in coronavirus disease (COVID-19) patients. Objective To determine whether ivermectin treatment can...
Shouman: Use of Ivermectin as a Potential Chemoprophylaxis for COVID-19 in Egypt: A Randomised Clinical Trial
Shouman, 304 patient ivermectin prophylaxis RCT: 91% fewer symptomatic cases [p=0.001] and 93% lower severe cases [p=0.002]. PEP trial for asymptomatic close..
Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19
This randomized trial compares the effects of ivermectin vs placebo on time to symptom resolution within 21 days among patients with mild COVID-19.
SAGE Journals: Your gateway to world-class research journals
Subscription and open access journals from SAGE Publishing, the world's leading independent academic publisher.
Error - Cookies Turned Off
Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting
BACKGROUND: SARS-CoV-2 infection (COVID-19) is a potentially lethal disease that may progress into severe respiratory distress syndrome requiring ventilatorypapers.ssrn.com
Using ivermectin in treating of patients with mild COVID-19 | IJN
Clinical, biochemical and molecular evaluations of ivermectin mucoadhesive nanosuspension nasal spray in reducing upper respiratory symptoms of mild COVID-19
Longdom Publishing SL | Open Access Journals
Longdom Publishing SL is one of the leading international open access journals publishers, covering clinical, medical, and technology-oriented subjects
Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon
Objective: This study was designed to determine the efficacy of ivermectin, an FDA-approved drug, in producing clinical benefits and decreasing the viral load of SARS-CoV-2 among asymptomatic subjects that tested positive for this virus in Lebanon. Methods: A randomized controlled trial was...
Efficacy of Ivermectin in COVID-19 Patients with Mild to Moderate Disease
Objective To evaluate the efficacy of ivermectin (IVM) as an addition to the standard of care (SOC) treatment in COVID-19 patients with mild and moderate disease Materials and Methods A randomized clinical trial (Trial registration # [NCT04392713][1]) was carried out at Combined Military...
Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19 – A double-blind, randomized placebo-controlled trial
Background Ivermectin, an anti-parasitic agent, also has anti-viral properties. Our aim was to assess whether ivermectin can shorten the viral shedding in patients at an early-stage of COVID-19 infection. Methods The double-blinded trial compared patients receiving ivermectin 0·2 mg/kg for 3...
Cluster Randomised Trials - Ivermectin Repurposing For COVID-19 Treatment Of Outpatients With Mild Disease In Primary Health Care Centers
Background The emergency of COVID-19, along with the current difficulties in responding to the high demand for vaccines, requests to the scientific community to find alternative treatments based on reuse of drugs as a strategy to prevent the progression of the disease in patie...
A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness
Ivermectin, a US Food and Drug Administration-approved anti-parasitic agent, was found to inhibit severe acute respiratory syndrome coronavirus 2 (SAR…
Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial
Ivermectin is an antiparasitic drug which has in-vitro efficacy in reducing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) viral load. H…
Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients
In a prospective observational study (pre-AndroCoV Trial), the use of nitazoxanide, ivermectin and hydroxychloroquine demonstrated unexpected improvem…
Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial
There are limited antiviral options for the treatment of patients with COVID-19. Ivermectin (IVM), a macrocyclic lactone with a wide anti-parasitary s…
Are all these studies wrong? Maybe, but nobody has demonstrated that scientifically at all. Not even close. Is more research needed? Yes.
Its horse paste.Ignore the mindless low-IQ NPCBots dismissing it as "horse-paste", the reality is many doctors are using Ivermectin on the frontlines in the arsenal against covid, and here's a partial list of actual scientific studies that have so far found improved outcomes with early treatment Ivermectin:
Ivermectin shows clinical benefits in mild to moderate COVID19: a randomized controlled double-blind, dose-response study in Lagos
Summary Introduction. In vitro studies have shown the efficacy of Ivermectin (IV) to inhibit the SARS—CoV-2 viral replication, but questions remained as to in-v
Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial - BMC Infectious Diseases
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has changed our lives. The scientific community has been investigating re-purposed treatments to prevent disease progression in coronavirus disease (COVID-19) patients. Objective To determine whether ivermectin treatment can...
Shouman: Use of Ivermectin as a Potential Chemoprophylaxis for COVID-19 in Egypt: A Randomised Clinical Trial
Shouman, 304 patient ivermectin prophylaxis RCT: 91% fewer symptomatic cases [p=0.001] and 93% lower severe cases [p=0.002]. PEP trial for asymptomatic close..
Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19
This randomized trial compares the effects of ivermectin vs placebo on time to symptom resolution within 21 days among patients with mild COVID-19.
SAGE Journals: Your gateway to world-class research journals
Subscription and open access journals from SAGE Publishing, the world's leading independent academic publisher.
Error - Cookies Turned Off
Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting
BACKGROUND: SARS-CoV-2 infection (COVID-19) is a potentially lethal disease that may progress into severe respiratory distress syndrome requiring ventilatorypapers.ssrn.com
Using ivermectin in treating of patients with mild COVID-19 | IJN
Clinical, biochemical and molecular evaluations of ivermectin mucoadhesive nanosuspension nasal spray in reducing upper respiratory symptoms of mild COVID-19
Longdom Publishing SL | Open Access Journals
Longdom Publishing SL is one of the leading international open access journals publishers, covering clinical, medical, and technology-oriented subjects
Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon
Objective: This study was designed to determine the efficacy of ivermectin, an FDA-approved drug, in producing clinical benefits and decreasing the viral load of SARS-CoV-2 among asymptomatic subjects that tested positive for this virus in Lebanon. Methods: A randomized controlled trial was...
Efficacy of Ivermectin in COVID-19 Patients with Mild to Moderate Disease
Objective To evaluate the efficacy of ivermectin (IVM) as an addition to the standard of care (SOC) treatment in COVID-19 patients with mild and moderate disease Materials and Methods A randomized clinical trial (Trial registration # [NCT04392713][1]) was carried out at Combined Military...
Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19 – A double-blind, randomized placebo-controlled trial
Background Ivermectin, an anti-parasitic agent, also has anti-viral properties. Our aim was to assess whether ivermectin can shorten the viral shedding in patients at an early-stage of COVID-19 infection. Methods The double-blinded trial compared patients receiving ivermectin 0·2 mg/kg for 3...
Cluster Randomised Trials - Ivermectin Repurposing For COVID-19 Treatment Of Outpatients With Mild Disease In Primary Health Care Centers
Background The emergency of COVID-19, along with the current difficulties in responding to the high demand for vaccines, requests to the scientific community to find alternative treatments based on reuse of drugs as a strategy to prevent the progression of the disease in patie...
A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness
Ivermectin, a US Food and Drug Administration-approved anti-parasitic agent, was found to inhibit severe acute respiratory syndrome coronavirus 2 (SAR…
Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial
Ivermectin is an antiparasitic drug which has in-vitro efficacy in reducing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) viral load. H…
Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients
In a prospective observational study (pre-AndroCoV Trial), the use of nitazoxanide, ivermectin and hydroxychloroquine demonstrated unexpected improvem…
Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial
There are limited antiviral options for the treatment of patients with COVID-19. Ivermectin (IVM), a macrocyclic lactone with a wide anti-parasitary s…
Are all these studies wrong? Maybe, but nobody has demonstrated that scientifically at all. Not even close. Is more research needed? Yes.
don't worry - eventually IVM actually slows the "Soldiers" down its self.
They are called Iverretards
Is this the evolution of covidiots?
devolution maybe? descent to a lower or worse state.
Sign up with Google
